Abstract 465TiP
Background
Management of musculo-skeletal cancers patients has changed significantly with change in treatment paradigm from amputation to limb conservation. Limb Salvage Surgery (LSS) is now the standard of care. Moreover, increase in survival rates following advancement in the available multimodality treatment has lead to increased interest regarding the quality of life (QOL) and functional outcomes of the survivor patients. Unfortunately, all the QoL studies in published literature pertain to western population. This study aims to determine the functional outcomes and quality of life after performing limb salvage surgery in extremity sarcoma patients in Indian population in tertiary care hospital.
Trial design
Observational study Inclusion criteria- extremity sarcoma patients treated with either limb salvage surgery or amputation between the year Jan 2017 to Dec 2022. Extremities sarcomas includes bone tumors and soft tissue sarcomas between 14 and 50 years of age. Exclusion criteria-Non extremities sarcoma patients and patients with rotationplasty / turn-o-plasty procedures done Patients’ baseline socio-demographic and clinical characteristics (age, gender, morphology and the type of surgical intervention) as well as orthopedic or oncological complications occurring during the follow-up will be derived from the medical record. Questionnaires concerning QoL and functional outcomes which will be sent by post / telephonically or an interview with the investigators on outpatient basis. Assessment tools: Functional outcome will be measured using the Toronto extremity salvage score, Musculoskeletal tumor society score while Quality of life will be assessed using the EORTC QLQ-C30 QoL scale. Statistical Analysis: Descriptive analysis of quantitative parameters will be expressed as means and standard deviation. Categorical data will be expressed as absolute number and percentage. Independent Student's t-test will be used for testing of mean difference between independent groups. Cross tables will be generated and Chi square test will be used for testing of associations. P-value < 0.05 will be considered statistically significant. All analysis will be done using SPSS software, version 24.0.
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
YO11 - Satisfactory response after Rituximab-Bendamustin in Poor Performance Status Geriatric with Relapsed DLBCL
Presenter: Yasjudan Putra
Session: Poster viewing 06
YO12 - Allogeneic hematopoietic stem cell transplant in a case of acute myeloid leukaemia with end stage renal disease
Presenter: DEVYANI SURANGE
Session: Poster viewing 06
YO13 - Rosai-Dorfman Disease Presenting with Multiple Contiguous Lymphadenopathy: A Case Report
Presenter: Lean Marx Maaño
Session: Poster viewing 06
YO15 - Nasopharyngeal carcinoma in pregnancy: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO16 - New onset SIADH masquerading progression in esthesioneuroblastoma
Presenter: Muthu Manikandan
Session: Poster viewing 06
YO17 - Olfactory Neuroblastoma with Cervical Lymph Node Metastases in a 21- Year old Filipino Woman: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO18 - Challenges in Provision of Patient centered care with a Practical approach in a Resource-limited setting - Steven Johnson Syndrome – Toxic Epidermal Necrolysis (SJS-TEN) overlap related to Phenytoin use and review of logistical challenges related to care provision - a Case Report.
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO19 - Posterior Reversible Encephalopathy Syndrome associated with Pharmacological management of Bowel obstruction at the end of life – a review of two cases separated by 5 years
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO20 - A case of drug-induced large vessel vasculitis with hoarseness as the chief complaint caused by pegfilgrastim during chemotherapy
Presenter: Takuya Sato
Session: Poster viewing 06
YO23 - Neo-adjuvant immunotherapy in operable non-small cell lung carcinoma
Presenter: Padmini S N
Session: Poster viewing 06